Basic fibroblast growth factor upregulates survivin expression in hepatocellular carcinoma cells via a protein kinase B-dependent pathway

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 385-390

  Sun, Bo ^a,b   Xu, Haiyan ^c   Zhang, Gang ^d   Zhu, Yongbao ^b   Sun, Hukui ^a   Hou, Guihua ^a  

^a SHANDONG UNIVERSITY   (China)

^b Blood Center of Shandong Province   (China)

^c TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d Department of Clinical Laboratory The First People's Hospital of Zibo City   (China)

Author keywords

Basic fibroblast growth factor; Hepatocarcinoma; Protein kinase B; Survivin; Wortmannin

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SURVIVIN; WORTMANNIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANDROSTADIENES; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FIBROBLAST GROWTH FACTOR 2; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84878190603     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2479     Document Type: Article

References (41)

1. Hu M and Polyak K: Microenvironmental regulation of cancer development. Curr Opin Genet Dev 18: 27-34, 2008. (Pubitemid 351694443)
2. Bissell MJ and Radisky D: Putting tumours in context. Nat Rev Cancer 1: 46-54, 2001. (Pubitemid 33741880)
3. Radisky D, Hagios C and Bissell MJ: Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11: 87-95, 2001. (Pubitemid 32423284)
4. Klagsbrun M and Soker S: VEGF/VPF: The angiogenesis factor found? Curr Biol 3: 699-702, 1993.
5. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999. (Pubitemid 29038270)
6. Tran J, Rak J, Sheehan C, et al: Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264: 781-788, 1999.
7. Ouyang G, Liu M, Ruan K, et al: Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett 281: 213-219, 2009.
8. Zhang L, Bhojani MS, Ross BD and Rehemtulla A: Molecular imaging of protein kinases. Cell Cycle 7: 314-317, 2008. (Pubitemid 351366494)
9. Zhang L, Lee KC, Bhojani MS, et al: Molecular imaging of Akt kinase activity. Nat Med 13: 1114-1119, 2007. (Pubitemid 47517501)
10. Kunkel MT, Ni Q, Tsien RY, Zhang J and Newton AC: Spatio-temporal dynamics of protein kinase B/Akt signaling revealed by a genetically encoded fluorescent reporter. J Biol Chem 280: 5581-5587, 2005. (Pubitemid 40280036)
11. Harvey RD and Lonial S: PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 3: 639-647, 2007.
12. Yang L, Dan HC, Sun M, et al: Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64: 4394-4399, 2004. (Pubitemid 38856907)
13. Skrzypski M, Kaczmarek P and Le TT: Effects of orexin A on proliferation, survival, apoptosis and differentiation of 3T3-L1 preadipocytes into mature adipocytes. FEBS Lett 586: 4157-4164, 2012.
14. Jin P, Wang YH, Peng YG, Hu S, Lu Q and Yang LY: Effect of PI3K/AKT inhibitor on benign prostate hyperplasia and its mechanism: an experimental study. Zhonghua Nan Ke Xue 16: 1068-1075, 2010 (In Chinese).
15. Zhang HJ, Siu MK, Yeung MC, et al: Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis 32: 765-771, 2011.
16. Yang Q, Liu HY, Zhang YW, et al: Anandamide induces cell death through lipid rafts in hepatic stellate cells. J Gastroenterol Hepatol 25: 991-1001, 2010.
17. Altieri DC and Marchisio C: Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79: 1327-1333, 1999.
18. Yamamoto T and Tanigawa N: The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 34: 207-212, 2001.
19. Tamm I, Want Y, Sausville E, et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58: 5315-5320, 1998. (Pubitemid 28551107)
20. Altieri DC: Survivin versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589, 2003.
21. Kajiwara Y, Yamasaki F, Hama S, et al: Exression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97: 1077-1083, 2003. (Pubitemid 36173161)
22. Islam A, Kageyama H, Takada N, et al: High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 19: 617-623, 2000. (Pubitemid 30102912)
23. Ambrosini G, Adida C and Altieri D: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997. (Pubitemid 27353455)
24. Ngan CY, Yamamoto H, Takagi A, et al: Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci 99: 129-139, 2008. (Pubitemid 350239041)
25. Huang CK, Lee SO, Lai KP, et al: Targeting androgen receptor in bone marrow mesenchymal stem cells leads to better transplantation therapy efficacy in liver cirrhosis. Hepatology 57: 1550-1563, 2013.
26. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
27. Hahn WC and Weinberg RA: Modelling the molecular circuitry of cancer. Nat Rev Cancer 2: 331-341, 2002. (Pubitemid 37328946)
28. López-Maury L, Marguerat S and Bähler J: Tuning gene expression to changing environments: from rapid responses to evolutionary adaptation. Nat Rev Genet 9: 583-593, 2008.
29. Tateishi M, Ishida T, Mitsudomi T, Kaneko S and Sugimachi K: Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50: 7077-7080, 1990. (Pubitemid 20361116)
30. Brattstrom D, Bergqvist M, Hesselius P, Larsson A, Wagenius G and Brodin O: Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer. Lung Cancer 43: 55-62, 2004. (Pubitemid 38096292)
31. Sufen G, Xianghong Y, Yongxia C and Qian P: bFGF and PDGF-BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells. Cell Biol Int 35: 545-551, 2011.
32. Drevs J, Zirrgiebel U and Schmidt-Gersbach CI: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16: 558-565, 2005. (Pubitemid 40613321)
33. Feng X, Zhang B, Wang J, et al: Adenovirus-mediated transfer of siRNA against basic fibroblast growth factor mRNA enhances the sensitivity of glioblastoma cells to chemotherapy. Med Oncol 28: 24-30, 2011.
34. Wang H, Rubin M, Fenig E, et al: Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res 57: 1750-1757, 1997. (Pubitemid 27199670)
35. Shankland SJ, Pippin J, Flanagan M, et al: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 51: 1088-1099, 1997. (Pubitemid 27186534)
36. Johnson MR, Valentine C, Basilio C and Mansukhani A: FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells. Oncogene 16: 2647-2656, 1998. (Pubitemid 28264042)
37. Carmeliet P, Lampugnani MG, Moons L, et al: Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98: 147-157, 1999. (Pubitemid 29344903)
38. Kim JW, Ho WJ and Wu BM: The role of the 3D environment in hypoxia-induced drug and apoptosis resistance. Anticancer Res 31: 3237-3245, 2011.
39. Gerber HP, Dixit V and Ferrara N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273: 13313-13316, 1998. (Pubitemid 28246905)
40. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V and Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336-30343, 1998. (Pubitemid 28545503)
41. Li F, Ambrosini G, Chu EY, Plescia J, et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396: 580-584, 1998. (Pubitemid 28563719)